Abstract
Capturing both genomic and nongenomic mechanisms of retinoblastoma gene dysfunction has potential to improve risk stratification and patient selection for biomarker-driven therapy. A 186-gene expression signature is capable of identifying Rb loss across cancer types, providing a new framework for assessing Rb dysfunction based on transcriptome data.See related article by Chen et al., p. 4290.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have